Organogenesis Holdings Inc., formerly Avista Healthcare Public Acquisition Corp, is a regenerative medicine company.
Description: Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets.
The stock's open price was 20.06. Get the latest Organogenesis Holdings detailed stock quotes, stock trade data, stock price info, and performance analysis, including Organogenesis investment advice, charts, stats and more. Organogenesis Holdings Inc. is located in Canton, MA, United States and is part of the Investment Firms Industry. Organogenesis Holdings Inc. has 525 total employees across all of its locations and generates $260.98 million in sales (USD).
The following materials from the Annual Report of Organogenesis Holdings Inc. on Form 10-K for the year ended December 31, 2019, formatted in XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets as of December 31, 2019 and December 31, 2018 of Organogenesis Holdings Inc., (ii) Consolidated Statements of Operations for the years ended December 31, 2019, 2018, and 2017 Organogenesis Holdings Inc. (NASDAQ:ORGO) Q4 2020 Earnings Conference Call March 16, 2021 5:00 PM ET Company Participants. Gary Gillheeney - President and CEO. Dave Francisco - CFO. Conference CANTON, Mass. _ Organogenesis Holdings Inc. on Tuesday reported fourth-quarter net income of $18.5 million, after reporting a loss in the same period a year earlier. 2021-02-10 · Organogenesis Holdings Inc. (NASDAQ:ORGO) has a beta value of 1.32 and has seen 1,130,786 shares traded in the last trading session.
Organogenesis Holdings: Accumulate On Dips (NASDAQ Why Pure Storage, VirnetX Organogenesis Holdings Inc (ORGO) Stock Trend - Moving Up Or ..
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the three and twelve months ended December 31, 2020 and introduced financial guidance expectations for fiscal year ended December 31, 2021. Organogenesis Holdings Inc. is a leading regenerative medicine company focused on empowering healing through the development, manufacturing and sale of products for the advanced wound care, and surgical and sports medicine markets. Data Provided by Refinitiv. Organogenesis Holdings Inc. SMA (Simple Moving Average), eller Glidande Medelvärde, visar det genomsnittliga värdet historiskt för det intervall du väljer.
Dec 10, 2018 Organogenesis Holdings Inc. Announces Completion Of Merger Of Avista Healthcare Public Acquisition Corp. And Organogenesis Inc.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now. A look at the stock’ 2021-04-20 · Organogenesis Holdings Inc. Cl A Organogenesis Holdings, Inc. is a regenerative medical company.
The company has a Forward Dividend ratio of 0, with its dividend yield at 0%. Organogenesis Holdings Inc., formerly Avista Healthcare Public Acquisition Corp, is a regenerative medicine company. Organogenesis Holdings, Inc. is a regenerative medical company.
Kommunal ordförande
It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs.
Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. Organogenesis Holdings Inc. (NASDAQ:ORGO) has been given an average recommendation of "Buy" by the six analysts that are covering the stock, Marketbeat Ratings reports.
Teacher training yoga
2021-04-06 · Organogenesis Holdings Inc. [NASDAQ: ORGO] traded at a high on 04/01/21, posting a 8.84 gain after which it closed the day’ session at $19.83. The company report on March 17, 2021 that Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2020 Financial Results; Introduces Fiscal Year
The stock has moved higher by 33.8% in the past month, while it is also above its 20 day SMA Organogenesis Holdings Inc. operates as a holding company. The Company, through its subsidiaries, focuses on development, manufacturing, and commercializing drugs and medicines for wound care, 2021-04-22 · Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2021 Financial Results on May 10, 2021 CANTON, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of pr 1 week ago - GlobeNewsWire Organogenesis Holdings Inc. - Class A: ISIN-Sektor-Bransch-Kortnamn: ORGO: Introduktionsdatum-Belåningsgrad-Säkerhetskrav: 200 % Organogenesis Holdings Inc. (NASDAQ:ORGO) has been given an average recommendation of "Buy" by the six analysts that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. Check the real-time ORGO stock price on the NASDAQ exchange and access historical data for Organogenesis Holdings, Inc. stock. Instantly find out the Organogenesis Holdings, Inc. stock quote Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the 1 dag sedan · Organogenesis Holdings Inc. (NASDAQ:ORGO) price on Friday, Apr 23, rose 3.38% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $22.05.